374 related articles for article (PubMed ID: 30369061)
1. Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8.
Stoddard SV; May XA; Rivas F; Dodson K; Vijayan S; Adhika S; Parker K; Watkins DL
Mol Inform; 2019 Mar; 38(3):e1800080. PubMed ID: 30369061
[TBL] [Abstract][Full Text] [Related]
2. Rational design of selective HDAC2 inhibitors for liver cancer treatment: computational insights into the selectivity mechanism through molecular dynamics simulations and QM/MM calculations.
Yang Y; Hu B; Yang Y; Gong K; Wang H; Guo Q; Tang X; Li Y; Wang J
Phys Chem Chem Phys; 2021 Aug; 23(32):17576-17590. PubMed ID: 34369509
[TBL] [Abstract][Full Text] [Related]
3. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.
Tabackman AA; Frankson R; Marsan ES; Perry K; Cole KE
J Struct Biol; 2016 Sep; 195(3):373-378. PubMed ID: 27374062
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants.
Marek M; Shaik TB; Heimburg T; Chakrabarti A; Lancelot J; Ramos-Morales E; Da Veiga C; Kalinin D; Melesina J; Robaa D; Schmidtkunz K; Suzuki T; Holl R; Ennifar E; Pierce RJ; Jung M; Sippl W; Romier C
J Med Chem; 2018 Nov; 61(22):10000-10016. PubMed ID: 30347148
[TBL] [Abstract][Full Text] [Related]
5. Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine.
Muth M; Jänsch N; Kopranovic A; Krämer A; Wössner N; Jung M; Kirschhöfer F; Brenner-Weiß G; Meyer-Almes FJ
Biochim Biophys Acta Gen Subj; 2019 Mar; 1863(3):577-585. PubMed ID: 30611847
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of class IIa histone deacetylase activity by gallic acid, sulforaphane, TMP269, and panobinostat.
Choi SY; Kee HJ; Jin L; Ryu Y; Sun S; Kim GR; Jeong MH
Biomed Pharmacother; 2018 May; 101():145-154. PubMed ID: 29482060
[TBL] [Abstract][Full Text] [Related]
7.
V Stoddard S; Dodson K; Adams K; L Watkins D
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905609
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity.
Heimburg T; Kolbinger FR; Zeyen P; Ghazy E; Herp D; Schmidtkunz K; Melesina J; Shaik TB; Erdmann F; Schmidt M; Romier C; Robaa D; Witt O; Oehme I; Jung M; Sippl W
J Med Chem; 2017 Dec; 60(24):10188-10204. PubMed ID: 29190092
[TBL] [Abstract][Full Text] [Related]
9. Preparation of a new construct of human histone deacetylase 8 for the crystallization of enzyme-inhibitor complexes.
Porter NJ; Christianson DW
Methods Enzymol; 2019; 626():561-585. PubMed ID: 31606091
[TBL] [Abstract][Full Text] [Related]
10. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
11. Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities.
Ortore G; Di Colo F; Martinelli A
J Chem Inf Model; 2009 Dec; 49(12):2774-85. PubMed ID: 19947584
[TBL] [Abstract][Full Text] [Related]
12. Hydroxamates of para-aminobenzoic acid as selective inhibitors of HDAC8.
Kulandaivelu U; Chilakamari LM; Jadav SS; Rao TR; Jayaveera KN; Shireesha B; Hauser AT; Senger J; Marek M; Romier C; Jung M; Jayaprakash V
Bioorg Chem; 2014 Dec; 57():116-120. PubMed ID: 25462986
[TBL] [Abstract][Full Text] [Related]
13. Novel urushiol derivatives as HDAC8 inhibitors: rational design, virtual screening, molecular docking and molecular dynamics studies.
Zhou H; Wang C; Deng T; Tao R; Li W
J Biomol Struct Dyn; 2018 Jun; 36(8):1966-1978. PubMed ID: 28632421
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
[TBL] [Abstract][Full Text] [Related]
15. Thermodynamics of binding of structurally similar ligands to histone deacetylase 8 sheds light on challenges in the rational design of potent and isozyme-selective inhibitors of the enzyme.
Singh RK; Suzuki T; Mandal T; Balsubramanian N; Haldar M; Mueller DJ; Strode JA; Cook G; Mallik S; Srivastava DK
Biochemistry; 2014 Dec; 53(48):7445-58. PubMed ID: 25407689
[TBL] [Abstract][Full Text] [Related]
16. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies.
Kashyap K; Kakkar R
J Biomol Struct Dyn; 2020 Jan; 38(1):48-65. PubMed ID: 30633630
[TBL] [Abstract][Full Text] [Related]
17. Exploring the potential binding sites of some known HDAC inhibitors on some HDAC8 conformers by docking studies.
Sixto-López Y; Gómez-Vidal JA; Correa-Basurto J
Appl Biochem Biotechnol; 2014 Aug; 173(7):1907-26. PubMed ID: 24888409
[TBL] [Abstract][Full Text] [Related]
18. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
Wang DF; Helquist P; Wiech NL; Wiest O
J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L
Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834
[TBL] [Abstract][Full Text] [Related]
20. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
